top of page

Amgen presents new data for Kyprolis in multiple myeloma at EHA

Amgen has announced results from a post-hoc analysis of the Phase III ASPIRE study which highlighted the benefit of continued treatment with Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) in patients with relapsed multiple myeloma.

Click on this link for more information.

source: http://www.europeanpharmaceuticalreview.com/41701/news/industry-news/amgen-kyprolis-eha/

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page